BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, MRI working group of the IPSCSG. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017;66:1675-1688. [PMID: 28555945 DOI: 10.1002/hep.29293] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Chazouillères O, Potier P, Bouzbib C, Hanslik B, Heurgue A, NGuyen-Khac E, Gournay J, Tanne F, Bureau C, Bourlière M, Ganne-Carrié N, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY SCLEROSING CHOLANGITIS. Clin Res Hepatol Gastroenterol 2021;:101775. [PMID: 34332142 DOI: 10.1016/j.clinre.2021.101775] [Reference Citation Analysis]
2 Peiseler M, Reiners D, Pinnschmidt HO, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Rösch T, Weiler-Normann C, Lohse AW, Schramm C. Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. PLoS One 2018;13:e0202686. [PMID: 30125307 DOI: 10.1371/journal.pone.0202686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zenouzi R, Liwinski T, Yamamura J, Weiler-normann C, Sebode M, Keller S, Lohse AW, Schramm C; the International PSC Study Group (IPSCSG). Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Aliment Pharmacol Ther 2018;48:169-78. [DOI: 10.1111/apt.14797] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
4 Waldthaler A, Schramm C, Bergquist A. Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis. Eur J Med Genet 2021;64:104231. [PMID: 33905896 DOI: 10.1016/j.ejmg.2021.104231] [Reference Citation Analysis]
5 Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach. Hepatol Int 2021;15:6-20. [PMID: 33377990 DOI: 10.1007/s12072-020-10118-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Montano-loza AJ, Allegretti JR, Cheung A, Ebadi M, Jones D, Kerkar N, Levy C, Rizvi S, Vierling JM, Alvarez F, Bai W, Gilmour S, Gulamhusein A, Guttman O, Hansen BE, Macparland S, Mason A, Onofrio F, Santamaria P, Stueck A, Swain M, Vincent C, Ricciuto A, Hirschfield G. Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. CanLivJ 2021;4:401-25. [DOI: 10.3138/canlivj-2021-0006] [Reference Citation Analysis]
7 Keller S, Venkatesh SK, Avanesov M, Weinrich JM, Zenouzi R, Schramm C, Adam G, Yamamura J. Gadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians? Clin Radiol. 2018;73:677.e1-677.e6. [PMID: 29576223 DOI: 10.1016/j.crad.2018.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
9 Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. Mayo Clin Proc 2020;95:2263-79. [PMID: 33012354 DOI: 10.1016/j.mayocp.2020.01.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nguyen L, Cazzagon N, Corpechot C, El Mouhadi S, Lemoinne S, Chazouillères O, Arrivé L. Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis. Eur Radiol 2019;29:1460-8. [DOI: 10.1007/s00330-018-5697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Deneau MR, Mack C, Perito ER, Ricciuto A, Valentino PL, Amin M, Amir AZ, Aumar M, Auth M, Broderick A, DiGuglielmo M, Draijer LG, Tavares Fagundes ED, El-Matary W, Ferrari F, Furuya KN, Gupta N, Hochberg JT, Homan M, Horslen S, Iorio R, Jensen MK, Jonas MM, Kamath BM, Kerkar N, Kim KM, Kolho KL, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Martinez M, Miethke A, Miloh T, Mogul D, Mohammad S, Mohan P, Moroz S, Ovchinsky N, Palle S, Papadopoulou A, Rao G, Rodrigues Ferreira A, Sathya P, Schwarz KB, Shah U, Shteyer E, Singh R, Smolka V, Soufi N, Tanaka A, Varier R, Vitola B, Woynarowski M, Zerofsky M, Zizzo A, Guthery SL. The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children. Hepatology 2021;73:1074-87. [PMID: 32464706 DOI: 10.1002/hep.31393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kozaka K, Sheedy SP, Eaton JE, Venkatesh SK, Heiken JP. Magnetic resonance imaging features of small-duct primary sclerosing cholangitis. Abdom Radiol (NY) 2020;45:2388-99. [PMID: 32417935 DOI: 10.1007/s00261-020-02572-w] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Vinnitskaya EV, Abdulkhakov SR, Abdurakhmanov DT, Alikhanov RB, Bakulin IG, Belousova EA, Bueverov AO, Burnevitch EZ, Efanov MG, Eremina EY, Ignatova ТМ, Ilchenko LY, Karmazanovsky GG, Knyazev OV, Kulezneva YV, Lopatkina TN, Nekrasova TP, Nikitin IG, Pavlenko VV, Parfenov AI, Podymova SD, Raichelson KL, Reisis AR, Sayfutdinov RG, Skazyvaeva EV, Syutkin VE, Khomeriki SG, Haimenova TY, Sandler YG. Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018). Ter Arkh 2019;91:9-15. [PMID: 31094167 DOI: 10.26442/00403660.2019.02.000075] [Reference Citation Analysis]
14 Grigoriadis A, Ringe KI, Andersson M, Kartalis N, Bergquist A. Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. Eur J Radiol 2021;142:109884. [PMID: 34380098 DOI: 10.1016/j.ejrad.2021.109884] [Reference Citation Analysis]
15 Eaton JE, Welle CL, Bakhshi Z, Sheedy SP, Idilman IS, Gores GJ, Rosen CB, Heimbach JK, Taner T, Harnois DM, Lindor KD, LaRusso NF, Gossard AA, Lazaridis KN, Venkatesh SK. Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology 2021;73:1868-81. [PMID: 32974892 DOI: 10.1002/hep.31575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Kumar N, Poddar U, Yadav R, Lal H, Pani K, Yachha SK, Srivastava A, Pandey R. Autoimmune Sclerosing Cholangitis in Children: A Prospective Case-Control Study. Pediatr Gastroenterol Hepatol Nutr 2021;24:154-63. [PMID: 33833971 DOI: 10.5223/pghn.2021.24.2.154] [Reference Citation Analysis]
17 Keller S, Aigner A, Zenouzi R, Kim AC, Meijer A, Weidemann SA, Krech T, Lohse AW, Adam G, Schramm C, Yamamura J. Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. PLoS One. 2018;13:e0193929. [PMID: 29513767 DOI: 10.1371/journal.pone.0193929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tenca A, Mustonen H, Lind K, Lantto E, Kolho K, Boyd S, Arola J, Jokelainen K, Färkkilä M. The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver Int 2018;38:2329-39. [DOI: 10.1111/liv.13899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L. Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology. 2018;68:1174-1188. [PMID: 29574971 DOI: 10.1002/hep.29882] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
20 Liwinski T, Schramm C. [Primary sclerosing cholangitis : Current diagnostics and treatment]. Internist (Berl) 2018;59:551-9. [PMID: 29700559 DOI: 10.1007/s00108-018-0428-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ringe KI, Vo Chieu VD, Wacker F, Lenzen H, Manns MP, Hundt C, Schmidt B, Winther HB. Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. Eur Radiol. 2021;31:2482-2489. [PMID: 32974688 DOI: 10.1007/s00330-020-07323-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
23 Rupp C, Hippchen T, Bruckner T, Klöters-Plachky P, Schaible A, Koschny R, Stiehl A, Gotthardt DN, Sauer P. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019;68:2170-8. [PMID: 30910856 DOI: 10.1136/gutjnl-2018-316801] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
24 Ismail MF, Hirschfield GM, Hansen B, Tafur M, Elbanna KY, Goldfinger MH, Ridgway GR, Jhaveri KS. Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. Eur Radiol 2021. [PMID: 34231037 DOI: 10.1007/s00330-021-08142-y] [Reference Citation Analysis]
25 Fung BM, Tabibian JH. Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. Liver Res 2019;3:106-17. [PMID: 31341699 DOI: 10.1016/j.livres.2019.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
26 Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391:2547-2559. [PMID: 29452711 DOI: 10.1016/s0140-6736(18)30300-3] [Cited by in Crossref: 105] [Cited by in F6Publishing: 39] [Article Influence: 26.3] [Reference Citation Analysis]
27 Ringe KI, Grigoriadis A, Halibasic E, Wacker F, Manns MP, Schramm C, Lenzen H; on behalf of the MRI working group of the IPSCSG. Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis. Hepatology 2019;69:1358-9. [DOI: 10.1002/hep.30276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Culver EL, Bungay HK, Betts M, Forde C, Buchel O, Manganis C, Warren BF, Cummings FR, Keshav S, Travis SPL, Chapman RW. Prevalence and long‐term outcome of sub‐clinical primary sclerosing cholangitis in patients with ulcerative colitis. Liver Int 2020;40:2744-57. [DOI: 10.1111/liv.14645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Gochanour E, Jayasekera C, Kowdley K. Primary Sclerosing Cholangitis: Epidemiology, Genetics, Diagnosis, and Current Management. Clin Liver Dis (Hoboken) 2020;15:125-8. [PMID: 32257124 DOI: 10.1002/cld.902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Tabibian JH, Ali AH, Lindor KD. Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. Gastroenterol Hepatol (NY). 2018;14:427-432. [PMID: 30166959 DOI: 10.6000/1927-7229.2012.01.01.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Ringe KI, Bergquist A, Lenzen H, Kartalis N, Manns MP, Wacker F, Grigoriadis A. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol 2020;129:109101. [PMID: 32505896 DOI: 10.1016/j.ejrad.2020.109101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020;36:77-84. [PMID: 31850928 DOI: 10.1097/MOG.0000000000000616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
33 Selvaraj EA, Culver EL, Bungay H, Bailey A, Chapman RW, Pavlides M. Evolving role of magnetic resonance techniques in primary sclerosing cholangitis. World J Gastroenterol 2019; 25(6): 644-658 [PMID: 30783369 DOI: 10.3748/wjg.v25.i6.644] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
34 Nair AV, Macdonald DB, Kelly EM, Satheesh S, Venugopalan P, Soman DK. Utility of MRCP in surveillance of primary sclerosing cholangitis associated hepatobiliary malignancy: 15 year experience at a single institution in Ontario, Canada. Clin Imaging 2022;81:47-53. [PMID: 34598005 DOI: 10.1016/j.clinimag.2021.08.007] [Reference Citation Analysis]
35 Cao JY, Artunduaga M, Schooler GR. Hepatic manifestations of systemic disease: an imaging-based review. Pediatr Radiol 2021. [PMID: 34797394 DOI: 10.1007/s00247-021-05222-5] [Reference Citation Analysis]
36 Cazzagon N, Chazouillères O, Corpechot C, El Mouhadi S, Chambenois E, Desaint B, Chaput U, Lemoinne S, Arrivé L. Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology 2019;43:387-94. [DOI: 10.1016/j.clinre.2019.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Björnsson ES, Kalaitzakis E. Recent advances in the treatment of primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 2021;15:413-25. [PMID: 33283566 DOI: 10.1080/17474124.2021.1860751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Grigoriadis A, Morsbach F, Voulgarakis N, Said K, Bergquist A, Kartalis N. Inter-reader agreement of interpretation of radiological course of bile duct changes between serial follow-up magnetic resonance imaging/3D magnetic resonance cholangiopancreatography of patients with primary sclerosing cholangitis. Scand J Gastroenterol 2020;55:228-35. [PMID: 32024405 DOI: 10.1080/00365521.2020.1720281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Goldfinger MH, Ridgway GR, Ferreira C, Langford CR, Cheng L, Kazimianec A, Borghetto A, Wright TG, Woodward G, Hassanali N, Nicholls RC, Simpson H, Waddell T, Vikal S, Mavar M, Rymell S, Wigley I, Jacobs J, Kelly M, Banerjee R, Brady JM. Quantitative MRCP Imaging: Accuracy, Repeatability, Reproducibility, and Cohort-Derived Normative Ranges. J Magn Reson Imaging 2020;52:807-20. [PMID: 32147892 DOI: 10.1002/jmri.27113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
40 Khoshpouri P, Ameli S, Ghasabeh MA, Pandey A, Zarghampour M, Varzaneh FN, Jacob A, Pandey P, Luo Y, Kamel IR. Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score. Eur J Radiol 2018;108:254-60. [PMID: 30396665 DOI: 10.1016/j.ejrad.2018.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
41 Song C, Lewis S, Kamath A, Hectors S, Putra J, Kihira S, Bane O, Ahmad J, Babb J, Thung S, Taouli B. Primary sclerosing cholangitis: diagnostic performance of MRI compared to blood tests and clinical scoring systems for the evaluation of histopathological severity of disease. Abdom Radiol (NY) 2020;45:354-64. [PMID: 31844914 DOI: 10.1007/s00261-019-02366-9] [Reference Citation Analysis]
42 Richardson N, Ng STH, Wraith DC. Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases. Front Immunol 2020;11:1586. [PMID: 32793226 DOI: 10.3389/fimmu.2020.01586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Schulze J, Lenzen H, Hinrichs JB, Ringe B, Manns MP, Wacker F, Ringe KI. An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2019;17:192-199.e3. [PMID: 29775791 DOI: 10.1016/j.cgh.2018.05.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Welle CL, Navin PJ, Olson MC, Hoodeshenas S, Torbenson MS, Venkatesh SK. MR elastography in primary sclerosing cholangitis: a pictorial review. Abdom Radiol (NY) 2022. [PMID: 35567617 DOI: 10.1007/s00261-022-03529-x] [Reference Citation Analysis]
45 Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis. 2018;38:160-169. [PMID: 29871021 DOI: 10.1055/s-0038-1655775] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
46 Bhat P, Aabakken L. Role of Endoscopy in Primary Sclerosing Cholangitis. Clin Endosc 2021;54:193-201. [PMID: 32380796 DOI: 10.5946/ce.2020.019-IDEN] [Reference Citation Analysis]
47 Barner-rasmussen N, Pukkala E, Jussila A, Färkkilä M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scandinavian Journal of Gastroenterology 2020;55:74-81. [DOI: 10.1080/00365521.2019.1707277] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
48 Eaton JE, Sen A, Hoodeshenas S, Schleck CD, Harmsen WS, Gores GJ, LaRusso NF, Gossard AA, Lazaridis KN, Venkatesh SK. Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2020;18:1576-1583.e1. [PMID: 31683058 DOI: 10.1016/j.cgh.2019.10.041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
49 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671 [PMID: 30783370 DOI: 10.3748/wjg.v25.i6.659] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 26] [Article Influence: 13.7] [Reference Citation Analysis]
50 Lemoinne S, Cazzagon N, Chazouillères O, Corpechot C, Arrivé L. Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC. Aliment Pharmacol Ther 2021;53:1329-30. [PMID: 34029414 DOI: 10.1111/apt.16378] [Reference Citation Analysis]
51 Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58:134-149. [PMID: 31463807 DOI: 10.1007/s12016-019-08764-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
52 Cazzagon N, Lemoinne S, El Mouhadi S, Trivedi PJ, Gaouar F, Kemgang A, Ben Belkacem K, Floreani A, Hirschfield G, Chretien Y, Housset C, Motta R, Russo FP, Chazouillères O, Arrivé L, Corpechot C. The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. Am J Gastroenterol 2019;114:1878-85. [PMID: 31738286 DOI: 10.14309/ajg.0000000000000461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
53 Selvaraj EA, Ba-Ssalamah A, Poetter-Lang S, Ridgway GR, Brady JM, Collier J, Culver EL, Bailey A, Pavlides M. A Quantitative Magnetic Resonance Cholangiopancreatography Metric of Intrahepatic Biliary Dilatation Severity Detects High-Risk Primary Sclerosing Cholangitis. Hepatol Commun 2021. [PMID: 34802195 DOI: 10.1002/hep4.1860] [Reference Citation Analysis]
54 Lemoinne S, Cazzagon N, El Mouhadi S, Trivedi PJ, Dohan A, Kemgang A, Ben Belkacem K, Housset C, Chretien Y, Corpechot C, Hirschfield G, Floreani A, Motta R, Gallix B, Barkun A, Barkun J, Chazouillères O, Arrivé L. Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 2019;17:2785-2792.e3. [DOI: 10.1016/j.cgh.2019.03.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]